TBS publications

More than 1,600 peer-reviewed publications underpin Trabecular Bone Score^® (TBS^®) as the global standard in bone microarchitecture assessment.

Filter a curated database of publications below, or search PubMed for all TBS^® publications.

Filter by keyword:

2023

Endocrinological Investigation

High Prevalence of Vertebral Deformity in Tumor-induced Osteomalacia Associated with Impaired Bone Microstructure

Ni, X., Guan, W., Jiang, Y., Li, X., Chi, Y., Pang, Q., Liu, W., Jiajue, R., Wang, O., Li, M., Xing, X., Wu, H., Huo, L., Liu, Y., Jin, J., Zhou, X., Lv, W., Zhou, L., Xia, Y., Gong, Y., Yu, W. and Xia, W.

EndocrinologyOncologySecondary Osteoporosis

2023

Journal of Clinical Medicine

Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis

Al-Hashimi, L., Klotsche, J., Ohrndorf, S., Gaber, T. and Hoff, P.

Secondary Osteoporosis

2023

Osteoporosis International

Long-term Effect of Denosumab on Bone Microarchitecture as Assessed by Tissue Thickness-adjusted Trabecular Bone Score in Postmenopausal Women with Osteoporosis: Results from FREEDOM and its Open-label Extension

Hans, D., McDermott, M., Huang, S., Kim, M., Shevroja, E. and McClung, M.

Primary Osteoporosis

2024

Osteoporosis International

Damaged Bone Microarchitecture by Trabecular Bone Score (TBS) and Low Appendicular Muscle Mass: Main Risk Factors for Vertebral and Non-Vertebral Fractures in Women with Long-standing Rheumatoid Arthritis

Silva, F.F., Machado, G.R., Ribeiro, A.C.M., Bonfiglioli, K.R., Shimabuco, A.Y., Figueiredo, C.P., Guerra, L.M.T., Caparbo, V.F., Pereira, R.M.R. and Domiciano, D.S.

Fracture Risk AssessmentRheumatologySecondary Osteoporosis

2023

Osteoporosis International

Update on the Clinical use of Trabecular Bone Score (TBS) in the Management of Osteoporosis: Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the Auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging

Shevroja, E., Reginster, J.-Y., Lamy, O., Al-Daghri, N., Chandran, M., Demoux-Baiada, A.-L., Kohlmeier, L., Lecart, M.-P., Messina, D., Camargos, B.M., Payer, J., Tuzun, S., Veronese, N., Cooper, C., McCloskey, E.V. and Harvey, N.C.

Fracture Risk AssessmentPrimary OsteoporosisSecondary OsteoporosisTreatment decision

2022

Osteoporosis International

Updated Trabecular Bone Score Accounting for the Soft Tissue Thickness (TBSTT) Demonstrated Significantly Improved Bone Microstructure with Denosumab in the FREEDOM TBS Post Hoc Analysis

Hans, D., Shevroja, E., McDermott, M., Huang, S., Kim, M. and McClung, M.

Primary OsteoporosisSoft Tissue

See the science in practice

We help clinicians reveal more from routine imaging — every patient, every scan — for better care.

Explore TBS Osteo Explore TBS Reveal Explore TBS Ortho

TBS Osteo™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Osteo is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). TBS Osteo is FDA 510(k) cleared (K243218) for use in the United States. TBS Osteo is included on the Australian Register of Therapeutic Goods (ARTG No. 528950) as "Inovanz Pty Ltd — X-ray system, diagnostic, general-purpose, application program software". Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.

RBfracture™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. RBfracture is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 0123). RBfracture is included on the Australian Register of Therapeutic Goods (ARTG No. 484605) as “Emergo Asia Pacific Pty Ltd T/a Emergo Australia - X-ray image interpretive software”. Manufacturer: Radiobotics ApS, Esplanaden 8C, 1tv, 1263, Copenhagen, Denmark. Always follow the instructions for use.

TBS Reveal™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Reveal is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). FDA clearance is pending; TBS Reveal is not available for clinical use in the United States. Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.

TBS Ortho™ is currently under development and is not yet CE marked, FDA cleared, or otherwise registered for clinical use in any jurisdiction. It is not available for purchase or clinical use at this time.